ClinicalTrials.gov
ClinicalTrials.gov Menu

VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00317239
Recruitment Status : Completed
First Posted : April 24, 2006
Results First Posted : November 25, 2013
Last Update Posted : February 20, 2018
Sponsor:
Information provided by (Responsible Party):
Luitpold Pharmaceuticals

Brief Summary:
This study compares the efficacy and safety of intravenous (IV) iron (VIT45) versus oral iron (ferrous sulfate) administered to subjects who suffer from anemia and are diagnosed with non-dialysis dependent chronic kidney disease (NDD-CKD).

Condition or disease Intervention/treatment Phase
Anemia Drug: Ferrous Sulfate tablets Drug: Ferric Carboxymaltose (FCM) Phase 3

Detailed Description:
This study compares the efficacy and safety of intravenous (IV) iron (VIT45) versus oral iron (ferrous sulfate) administered to subjects who suffer from anemia and are diagnosed with non-dialysis dependent chronic kidney disease (NDD-CKD).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 255 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Safety & Efficacy of a Unique Intravenous Iron (VIT45) Preparation vs Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Study Start Date : May 2005
Actual Primary Completion Date : February 2007
Actual Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Ferric Carboxymaltose (FCM)
A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
Drug: Ferric Carboxymaltose (FCM)
A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
Active Comparator: Ferrous Sulfate tablets
325 mg/TID x 8 weeks
Drug: Ferrous Sulfate tablets
325 mg/TID x 8 weeks



Primary Outcome Measures :
  1. Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL [ Time Frame: anytime during the study ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females > or = 12 years of age
  • NDD-CKD subjects
  • Baseline hemoglobin < or = 11g/dl
  • Stable erythropoietin (EPO) status

Exclusion Criteria:

  • Known hypersensitivity to ferrous sulfate or IV iron
  • Unstable EPO status
  • Anemia not related to CKD
  • Chronic, serious infection
  • Recent IV iron
  • Recent blood transfusion
  • Recent blood loss
  • Need for surgery
  • Received investigational drug within 30 days
  • Female subjects who are pregnant or lactating

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00317239


Locations
United States, Pennsylvania
Luitpold Pharmaceuticals
Norristown, Pennsylvania, United States, 19403
Sponsors and Collaborators
Luitpold Pharmaceuticals

Publications of Results:
Qunibi W, Martinez C, Smith M, Benjamin J, Mangione A. A Randomized Controlled Trial Comparing Intravenous Ferric Carboxymaltose to Oral Iron in Anemic Patients with Non-Dialysis-Dependent CKD. American Society of Nephrology Renal Week 2007.
Qunibi W, Martinez C, Smith M, Benjamin J, Dinh Q. A Randomized Controlled Trial Comparing IV Ferric Carboxymaltose (FCM) to Oral Iron in Anemic Patients with Non-Dialysis-Dependent CKD. American Society of Nephrology Renal Week 2007.

Responsible Party: Luitpold Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00317239     History of Changes
Other Study ID Numbers: 1VIT04004
First Posted: April 24, 2006    Key Record Dates
Results First Posted: November 25, 2013
Last Update Posted: February 20, 2018
Last Verified: January 2018

Keywords provided by Luitpold Pharmaceuticals:
Anemia
Chronic Kidney Disease
Iron

Additional relevant MeSH terms:
Anemia
Kidney Diseases
Renal Insufficiency, Chronic
Hematologic Diseases
Urologic Diseases
Renal Insufficiency
Ferric Compounds
Hematinics